In the following video, Motley Fool health-care analyst David Williamson looks at pharmaceutical company Corcept (NASDAQ: CORT ) for being one of the top-performing health-care stocks in January. Although shares were ripped in half when the company failed to launch its Cushing's disease drug Korlym in 2012, while competitor Novartis (NYSE: NVS ) did receive FDA approval for its drug in this space, Signifor, Corcept was able to rebound in January by up to 52%. David tells us why the amount of cash Corcept has on hand means the company has plenty of time to get things right next time.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of.�Click here now�to keep reading.
No comments:
Post a Comment